882PPotent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts). (23rd October 2018) - Verzoni, E; Ferro, S; Procopio, G; Cova, A; Ratta, R; Raimondi, A; Sepe, P; Squarcina, P; Lalli, L; Huber, V; Rinchai, D; Bedognetti, D; et al.